Rashid Fehmida Syed, 641587 Blue Canyon St, Thousand Oaks, CA 91320

2013023, Sep 5, 2013

Mar 4, 2013

13/784049

SANJAY KHARE - NEWBURY PARK CA, US
MICHAEL GRESSER - OJAI CA, US
RASHID SYED - THOUSAND OAKS CA, US

ImmunGene Inc. - Thousand Oaks CA

C07K 14/56
C07K 16/30

4241341, 530351

The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-α) mutant molecule. The engineered Ab-IFN-α mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-α fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-α fusion molecules.

6904369, Jun 7, 2005

Jun 29, 2000

09/609027

Wayne A. Hendrickson - New York NY, US
Xuliang Jiang - Braintree MA, US
Keith E. Langley - Newbury Park CA, US
Rashid Syed - Thousand Oaks CA, US

The Trustees of Columbia University in the City of New York - New York NY
Amgen Inc. - Thousand Oaks CA

G01N033/48
G01N033/50
A61K038/00
C07K001/00
C07H021/04

702 19, 702 20, 702 22, 530300, 530350, 536 231, 536 241

This invention provides a computer based method for preparing a stem cell factor (SCF) analog comprising the steps of: (a) providing computer expression of the three dimensional structure of an SCF molecule using its crystal structure; (b) selecting from the computer expression of step (a) at least one site on the SCF molecule for alteration; (c) preparing a SCF molecule having an alteration at said at least one selected site; and (d) optionally, testing the SCF molecule for a desired characteristic. This invention also provides SCF analogs and SCF ligand analogs prepared according to the above-described method. Compositions comprising SCF analogs or SCF ligand analogs prepared according to the above-described method effective to treat a subject and a pharmaceutically acceptable carrier are provided, as are methods of treating a subject comprising administration of pharmaceutical compositions comprising the prepared SCF analogs and SCF ligand analogs prepared by the described methods. This invention also provides methods for designing compounds capable of binding to the SCF receptor site and compounds designed by the above-described methods.

2017007, Mar 16, 2017

Nov 28, 2016

15/361902

- Camarillo CA, US
Sanjay Khare - Palo Alto CA, US
Michael Gresser - Ojai CA, US
Rashid Syed - Thousand Oaks CA, US

C07K 14/56
C07K 16/18
C07K 16/30
C07K 16/28

The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-α) mutant molecule. The engineered Ab-IFN-α mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-α fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-α fusion molecules.

2015013, May 21, 2015

Feb 2, 2015

14/611945

- CAMARILLO CA, US
Sanjay Khare - Palo Alto CA, US
Michael Gresser - Ojai CA, US
Rashid Syed - Thousand Oaks CA, US

C07K 16/28
A61K 38/21
C07K 16/32
A61K 39/395
A61K 45/06
C07K 14/56

424 857

The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-α) mutant molecule. The engineered Ab-IFN-α mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-α fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-α fusion molecules.

2014010, Apr 17, 2014

Jun 6, 2012

14/124565

Iqbal Grewal - Snohomish WA, US
Michael Gresser - Ojai CA, US
Sanjay Khare - Palo Alto CA, US
Rashid Syed - Thousand Oaks CA, US

IMMUNGENE INC - Thousand Oaks CA

C07K 16/28
A61K 45/06
A61K 39/395
C07K 14/525
A61K 38/19
A61K 38/21

424 857, 424 851, 4241341, 530350, 530351, 5303873

The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to engineered fusion molecules comprising an antibody (Ab) which can target tumor cells (e.g., RITUXIN), fused to one or more biologic moieties capable of inducing apoptosis in tumor cells, e.g., tumor necrosis factor super family (TNFSF) member ligands such as TNF-α, CD40L, CD95L (also “FasL/Apo-1L”) and TRAIL/Apo-2L. Importantly, the engineered fusion molecules of the present invention retain the death-inducing properties of the biologic moiety at optimum concentrations and with reduced systemic toxicities, thus improving the therapeutic index of the engineered fusion molecules.